Summary
The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Colombia, Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Colombia 2020 Forum is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Colombia and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speakers
Federico Odreman
Dean of the Natural Science Faculty. ICESI University, Colombia.
Claudia Vaca
Think Tank “Medicines, Information and Power” UNAL, Colombia. Founder and Head.
Eduardo Cioppi
mAbxience, Argentina. Regional Director – Latin America
Claudia Marcela Betancour
Biointropic, Colombia. Executive Director
Jose Josan
Universidad Peruana Cayetano Heredia, Peru Professor
Oscar César Bustamante García
Adium, Mexico
Regulatory Affairs Manager
Maria Yolanda Cervantes Apolinar
Former GSK, Mexico
Senior Consultant and Expert in Vaccines
Vinicius Marçal
Cytiva, Brazil
Business Development Manager
Latam Biosimilars’s Insight. Panel Industry Leaders
Edgar Mauricio Rubio
Indukern, Colombia
Pharmaceutical & Animal Health Division Manager
Eduardo Cioppi
mAbxience, Argentina
Regional Director – Latin America
Jaime Uribe
PROBIOMED, Mexico
CEO
Perception on Biosimilars from Local Patients and HCPs. Panel
Pharmacovigilance in Latam
Current Technology used in Latam for Biosimilars Development. Panel
International Standard for the Evaluation and Approval of Biologics/Biosimilars. Panel
What the Future of Biosimilars in Colombia is? Panel
Full programme in the PDF Agenda
Sponsors
Photo Gallery from Previous Events
Testimonials
-
"The main point was the people I met at the Congress, whose networking generated interviews and work placement alternatives for me."
Adriane Costa, Legal & Compliance Director At Compass Minerals
-
”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”
Alison Bascou, Sr. Regulatory Director at BD, France
-
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."
Jaime Uribe, CEO At PROBIOMED
-
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”
Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
-
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”
Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
-
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”
Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico